Publication | Closed Access

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation

TransplantationMarrow TransplantationMedicineTransplantation MedicineImmunologyHematologyCell Replacement TherapyTyrosine Kinase InhibitorsGraft SurvivalBlood TransplantationImmunotherapyOncologyCell TransplantationLong-term OutcomesDonor Lymphocyte Infusions